The Isabella

Isabella Therapeutics is a biotechnology company focused on developing novel treatments for neonatal abstinence syndrome (NAS) and other conditions related to maternal-fetal health. The company's lead program, ITX-101, is a small molecule designed to mitigate the symptoms of opioid withdrawal in newborns by targeting specific neurobiological pathways. By addressing the underlying mechanisms of withdrawal rather than just managing symptoms, Isabella Therapeutics aims to improve long-term outcomes for infants exposed to opioids in utero. The company is currently advancing its pipeline through pre-clinical studies with the goal of entering clinical trials to provide safer and more effective therapeutic options for this vulnerable population.